Abstract
Many neurodegenerative diseases are late onset diseases, associated with aggregation of proteins, implying that aged cells are more susceptible to proteotoxic stress. It is known that with aging, there is a decline in the functionality of chaperone networks and on the other hand, accumulation of damaged proteins occurs. Together, this has a cumulative effects on cellular protein homeostasis. Several studies have revealed that availability of DNAJ proteins, the cochaperones to the Hsp70 machine, could be a rate-limiting factor in handling diseased proteins within the cell. In this review, we highlight how DNAJ proteins can affect aggregation of disease-causing proteins, if and how this depends on their function as Hsp70 co-chaperones, and how much this depends on the type of protein causing the disease. Finally, we will discuss the five known degenerative diseases that are linked to mutations in individual DNAJ members and what mechanism may underlie these DNAJ chaperonopathies.
Keywords: Protein aggregation diseases, DNAJ proteins, neurodegeneration, Hsp70, chaperonopathies, protein quality control
Current Topics in Medicinal Chemistry
Title:DNAJ Proteins and Protein Aggregation Diseases
Volume: 12 Issue: 22
Author(s): Vaishali Kakkar, Louis C. B. Prins and Harm H. Kampinga
Affiliation:
Keywords: Protein aggregation diseases, DNAJ proteins, neurodegeneration, Hsp70, chaperonopathies, protein quality control
Abstract: Many neurodegenerative diseases are late onset diseases, associated with aggregation of proteins, implying that aged cells are more susceptible to proteotoxic stress. It is known that with aging, there is a decline in the functionality of chaperone networks and on the other hand, accumulation of damaged proteins occurs. Together, this has a cumulative effects on cellular protein homeostasis. Several studies have revealed that availability of DNAJ proteins, the cochaperones to the Hsp70 machine, could be a rate-limiting factor in handling diseased proteins within the cell. In this review, we highlight how DNAJ proteins can affect aggregation of disease-causing proteins, if and how this depends on their function as Hsp70 co-chaperones, and how much this depends on the type of protein causing the disease. Finally, we will discuss the five known degenerative diseases that are linked to mutations in individual DNAJ members and what mechanism may underlie these DNAJ chaperonopathies.
Export Options
About this article
Cite this article as:
Kakkar Vaishali, C. B. Prins Louis and H. Kampinga Harm, DNAJ Proteins and Protein Aggregation Diseases, Current Topics in Medicinal Chemistry 2012; 12 (22) . https://dx.doi.org/10.2174/1568026611212220004
DOI https://dx.doi.org/10.2174/1568026611212220004 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy
Current Drug Targets Cannabinoid System as a Potential Target for Drug Development in the Treatment of Cardiovascular Disease
Current Vascular Pharmacology Circadian Rhythm in Cytokines Administration
Mini-Reviews in Medicinal Chemistry An Update on Drug Interactions with the Herbal Medicine Ginkgo biloba
Current Drug Metabolism Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Genetics of Hypertrophic and Dilated Cardiomyopathy
Current Pharmaceutical Biotechnology Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity
Current Immunology Reviews (Discontinued) Transcranial Near-infrared Laser Therapy in Improving Cognitive Recovery of Function Following Traumatic Brain Injury
Current Neuropharmacology Imaging Studies in Hypercalcemia
Current Medicinal Chemistry Transcriptional Regulation in Mammalian Pituitary Development and Disease
Current Genomics Vitiligo: Pathogenetic Hypotheses and Targets for Current Therapies
Current Drug Metabolism Mouse Models of Primary Sjogren’s Syndrome
Current Pharmaceutical Design Microcirculatory Endothelial Dysfunction During Endotoxemia - Insights into Pathophysiology, Pathologic Mechanisms and Clinical Relevance
Current Vascular Pharmacology Pharmacological Inhibition of Interleukin-8 (CXCL8) as a New Approach for the Prevention and Treatment of Several Human Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis
Current Pharmaceutical Design A Role of Immunotherapy in Metastatic Malignant Melanoma
Central Nervous System Agents in Medicinal Chemistry The Prospect for Type 2 Diabetes Mellitus Combined with Exercise and Synbiotics: A Perspective
Current Diabetes Reviews Mitochondrial Complex I Deficiency in Humans
Current Genomics The Role of the Cytochrome P450 Polymorphisms in Clopidogrel Efficacy and Clinical Utility
Current Medicinal Chemistry